Video summary: Enzyme glycogen synthase kinase in carcinogenesis

A review article published in BiomolBiomed by authors from University of Zagreb, Croatia and Qatar University, Qatar, has shed light on the role of the enzyme glycogen synthase kinase (GSK) in ovarian cancer development. The article shows that GSK plays a critical role in carcinogenesis and that its activity is associated with advanced FIGO stages and elevated CA -125 levels in some tumors.

The article found that in some tumours, GSK promotes tumour development, while in others, it acts as a tumour suppressor. Moreover, treatment with a GSK3 inhibitor can reduce the growth of malignant cells, suggesting that GSK3 is a driving force in ovarian cancer development.

The article also highlights that various Akt activators decrease GSK3 activity, which promotes ovarian cancer development. In contrast, Akt inhibitors restitute GSK3 activity, which results in cancer growth arrest. These findings show that the exact role of GSK3 in ovarian cancer development is not clear yet, and there are two opposite therapeutic approaches targeting GSK3: activation and inhibition.

Many drugs are currently undergoing evaluation and clinical trials. Therefore, this article calls for further research to better understand the exact role of GSK3 in ovarian cancer development and develop targeted therapies for ovarian cancer patients.

For more information on this topic, please read the full article here. 

由克罗地亚萨格勒布大学和卡塔尔大学的作者在BiomolBiomed上发表的一篇评论文章,阐明了酶糖原合成酶激酶(GSK)在卵巢癌发展中的作用。该文章表明,GSK在癌变过程中起着至关重要的作用,并且其活性与某些肿瘤中进阶的FIGO阶段和升高的CA-125水平相关。

该文章发现,在某些肿瘤中,GSK促进肿瘤发展,而在其他肿瘤中,则充当肿瘤抑制剂。此外,使用GSK3抑制剂治疗可以减少恶性细胞的生长,表明GSK3是卵巢癌发展的推动力。

该文章还强调,各种Akt激活剂会降低GSK3的活性,从而促进卵巢癌的发展。相反,Akt抑制剂会恢复GSK3的活性,导致癌症生长停止。这些发现表明,GSK3在卵巢癌发展中的确切作用尚不清楚,并且有两种相反的针对GSK3的治疗方法:激活和抑制。

目前有许多药物正在评估和临床试验中。因此,该文章呼吁进一步研究,以更好地了解GSK3在卵巢癌发展中的确切作用,并为卵巢癌患者开发有针对性的治疗方法。

有关此主题的更多信息,请阅读完整文章。

Reference: Glibo M, Serman A, Karin-Kujundzic V, Bekavac Vlatkovic I, Miskovic B, Vranic S, Serman L. The role of glycogen synthase kinase 3 (GSK3) in cancer with emphasis on ovarian cancer development and progression: A comprehensive review. Biomol Biomed [Internet]. 2021Feb.1 [cited 2023Apr.29];21(1):5-18. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/5036

Be the first to comment

Leave a Reply